viewBenitec Biopharma

Benitec Biopharma begins phase II clinical study for head and neck cancer treatment

Drug sales for head and neck cancer treatment projected to rise to $1.53 billion in 2024.

a doctor examining a patient
The study will enrol up to 30 patients across Australia and Russia

Benitec Biopharma Ltd (ASX:BLT) (NASDAQ:BNTC) has commenced a phase II clinical study in Australia with BB-401 as a treatment for patients with head and neck squamous cell carcinoma (HNSCC).

The company is developing innovative therapeutics based on a combination of gene therapy and a patented gene-silencing technology called ddRNAi.

READ: Benitec Biopharma’s shares ride higher after securing new U.S. patent

The phase II open-label study has been designed to explore the safety, tolerability and efficacy of BB401 following injections into the lesions of patients with recurrent or metastatic head and neck cancer.

The study will enrol up to 30 patients at 5-8 sites across Australia and Russia.

Objective is to control the progression of cancer

BB-401 is a recombinant DNA (deoxyribonucleic acid) construct that produces an antisense RNA (ribonucleic acid) with specificity against Epidermal Growth Factor Receptor (EGFR).

More than 90% of lesions from patients show significantly increased EGFR levels associated with head and neck cancer.

The goal of this study is to inhibit the expression of EGFR in the treated lesions and thus control the progression of the disease and increase patient survival.

Significant market potential

In 2016, circa 64,000 new cases of head and neck cancer were estimated to have been diagnosed in the U.S., resulting in more than 13,000 deaths.

Total drugs sales for this type of cancer in the seven major markets (U.S., France, Germany, Italy, Spain, UK and Japan) is expected to increase from $386 million in 2014 to $1.53 billion in 2024.

Benitec’s new study represents an important milestone in the progression of BB-401 as a treatment option for patients with advanced head and neck cancer who have failed all other treatment modalities.

Quick facts: Benitec Biopharma

Price: - -

Market: ASX
Market Cap: -

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Jindalee Resources' Lindsay Dudfield talks plans to unlock value at its...

Jindalee Resources Ltd's (ASX:JRL) Lindsay Dudfield discusses with Proactive London's Andrew Scott the plans to advance its McDermitt US lithium project. Back in June they received encouraging metallurgical test-work results from the project which confirmed an increase in lithium head grade...

2 days, 9 hours ago

2 min read